CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2010-02-24): New hepatitis C drug shows good response in early trial

Drug & Device Development

New hepatitis C drug shows good response in early trial

Last Updated: 2010-02-24 19:48:03 -0400 (Reuters Health)

NEW YORK, Feb 24 (Reuters) - An experimental hepatitis C treatment produced impressive early response rates with no serious safety issues, according to preliminary data from a small phase II trial.

At 12 weeks of dosing, 73% of the 26 treatment-na�ve patients who received 200 mg of the non-nucleoside inhibitor ANA598 (Anadys Pharmaceuticals Inc) twice daily in combination with standard treatment had a complete virological response.

However, among the 14 patients in the control group, who received pegylated interferon and ribavirin plus placebo, the complete virological response rate was a much higher-than-expected 71%.

There was a much larger separation of response rates between the two treatment arms at weeks 4, 6, 8 and 10, when the ANA598 viral response was already at 73%, while the control group response was 54%.

The virtually identical 12-week response rate between the two arms may be due to the small number of patients and were likely skewed by the fact that 12-week data were missing from one patient from each group.

No one treated with ANA598 experienced viral rebound.

No serious adverse events were reported with ANA598, and the side effects that were observed, such as a rash, were comparable between the treatment and control groups.

Patients will continue to be treated through 24 or 48 weeks, with sustained virologic response rates becoming available toward the end of the year.

The early response rate for ANA598 is comparable to what has been seen for other promising hepatitis C treatments in clinical trials, while the control group response was far higher than what has been seen in those other studies.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.